Optimal dilutions for each application to be determined by the researcher. Prepare working dilution immediately before use.
Target
Alternative Names
duocarmycins;
Citations
Publication ()
Have you cited CABT-L3108 in a publication? Let us know and earn a reward for your research.
Background
Duocarmycins are a class of natural products that possess potent anti-cancer properties. They belong to the family of DNA-alkylating agents and are derived from bacterial sources, particularly Streptomyces bacteria. Duocarmycins are characterized by a unique spirocyclic structure that allows them to bind to the minor groove of DNA. This binding triggers alkylation of DNA, leading to strand breaks and ultimately cell death. The duocarmycin core structure consists of a DNA-binding left-hand cyclopropabenzoindoline (CBI) unit and a right-hand pharmacophore that enhances the compound's cytotoxicity.
The potent anti-cancer activity of Duocarmycins has attracted significant interest in the field of oncology. Researchers have explored the therapeutic potential of Duocarmycins and their derivatives for various types of cancer, including solid tumors and hematological malignancies. Preclinical studies have demonstrated promising results, showing significant anti-tumor efficacy in animal models and synergy with other anti-cancer agents. Efforts have also been made to develop Duocarmycin-based drugs for clinical use. These include the design and synthesis of analogs and prodrugs with improved pharmacological properties, such as enhanced stability, solubility, and targeted delivery. Furthermore, strategies like antibody-drug conjugates (ADCs) have been employed to selectively deliver Duocarmycins to cancer cells, minimizing off-target effects and improving the therapeutic index.
Anti-Duocarmycin Polyclonal Antibodies are a class of antibodies that specifically target and bind to Duocarmycin. These antibodies have been widely used in research and development applications related to Duocarmycin-based therapeutics. They serve as valuable tools for detecting and quantifying Duocarmycin in biological samples, such as cell lysates or patient samples, using techniques like enzyme-linked immunosorbent assay (ELISA) or Western blotting. These antibodies can also be employed for immunohistochemistry and immunofluorescence studies to visualize the localization and distribution of Duocarmycin within cells or tissues. Furthermore, Anti-Duocarmycin Polyclonal Antibodies play a crucial role in the development and characterization of Duocarmycin-based drugs. They aid in evaluating the pharmacokinetics and pharmacodynamics of these drugs, assessing their efficacy and safety profiles, and monitoring drug levels in preclinical and clinical studies.
My Review for Rabbit Anti-Duocarmycin polyclonal antibody
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
References
Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress
Drug Discovery Today
Authors: Yao, H. P., Zhao, H., Hudson, R., Tong, X. M., Wang, M. H.
Duocarmycins are a class of DNA minor-groove-binding alkylating molecules. For the past decade, various duocarmycin analogues have been used as payloads in the development of antibody–drug conjugates (ADCs). Currently, more than 15 duocarmycin-based ADCs have been studied preclinically, and some of them such as SYD985 have been granted Fast-Track Designation status. Nevertheless, progress in duocarmycin-based ADCs also faces challenges, with setbacks including the termination of BMS-936561/MDX-1203. In this review, we discuss issues associated with the efficacy, pharmacokinetic profile, and toxicological activity of these biotherapeutics. Furthermore, we summarize the latest advances in duocarmycin-based ADCs that have different target specificities and linker chemistries. Evidence from preclinical and clinical studies has indicated that duocarmycin-based ADCs are promising biotherapeutics for oncological application in the future.
How can the potential of the duocarmycins be unlocked for cancer therapy?
Drug Discovery Today
Authors: Jukes, Z., Morais, G. R., Loadman, P. M., Pors, K.
The duocarmycins belong to a class of agent that has fascinated scientists for over four decades. Their exquisite potency, unique mechanism of action, and efficacy in multidrug-resistant tumour models makes them attractive to medicinal chemists and drug hunters. However, despite great advances in fine-tuning biological activity through structure–activity relationship studies (SARS), no duocarmycin-based therapeutic has reached clinical approval. In this review, we provide an overview of the most promising strategies currently used and include both tumour-targeted prodrug approaches and antibody-directed technologies.
COA
Publication 
Loading ......
